Hebenstreit G F, Hoffmann H, Hoffmann W, Pittner H
Wien Klin Wochenschr. 1986 Jun 13;98(12):388-92.
The influence of celiprolol on the symptoms of tardive dyskinesia was compared with placebo in a randomized double blind study. 17 female patients were treated with a single daily dose of 200 mg celiprolol and 18 female patients received placebo for a period of 3 months. All patients got additional neuroleptic treatment. Celiprolol produced a small decrease in heart rate and systolic blood pressure, but had no influence on the diastolic blood pressure. The effects of celiprolol on the symptoms of tardive dyskinesia were similar to those of the placebo; in both groups improvements and deteriorations were observed. One patient of the celiprolol group became symptom free. Two cases of collapse occurred after 10 weeks of treatment with celiprolol. In one case collapse was associated with diarrhoea, in the other case the patient had preexisting hypotensive circulatory dysregulation. Sporadic reports about the effect of propranolol in patients with tardive dyskinesia might reflect the normal progress of the disease or the effect might depend on the different pharmacological profile of propranolol.
在一项随机双盲研究中,将塞利洛尔对迟发性运动障碍症状的影响与安慰剂进行了比较。17名女性患者每日单次服用200毫克塞利洛尔,18名女性患者服用安慰剂,为期3个月。所有患者均接受额外的抗精神病药物治疗。塞利洛尔使心率和收缩压略有下降,但对舒张压无影响。塞利洛尔对迟发性运动障碍症状的影响与安慰剂相似;两组均观察到症状改善和恶化情况。塞利洛尔组有1例患者症状消失。使用塞利洛尔治疗10周后发生了2例虚脱。1例虚脱与腹泻有关,另1例患者原有低血压循环调节障碍。关于普萘洛尔对迟发性运动障碍患者影响的零星报道可能反映了疾病的正常进展,或者其影响可能取决于普萘洛尔不同的药理学特性。